五味灵芪胶囊体外抗艾滋病毒活性的研究

Study on Anti-HIV-1 Activity of Wuweilingqi Capsule in Vitro

目的检测五味灵芪胶囊对不同艾滋病毒(HIV-1)株复制的抑制活性,与抗HIV-1药物的协同作用以及对CD4+、CD8+淋巴细胞的免疫增强活性。方法从中药复方制剂中分离提取的有效部位制成五味灵芪胶囊,利用人体外周血淋巴细胞(PBMC)和人T淋巴细胞系(H9和MT2)培养。结果五味灵芪胶囊在人PBMC中对临床分离株HIV-1018a的治疗指数为96,在人T淋巴细胞系H9和MT-2细胞中对HIV-1实验室株HTLV-ⅢB的治疗指数分别为94和181;与西药齐夫多定相比,它对HIV-1018c和慢性感染H9的病毒株抑制作用较弱;它与HIV-1逆转录酶抑制剂、蛋白酶抑制剂和阻止病毒进入的融合蛋白抑制剂有良好的协同抗病毒活性;显著提高PBMC对非特异抗原植物血凝素(PHA)及特异的抗原念珠菌(candidi)的反应能力。结论与西药齐夫多定相比,五味灵芪胶囊抑制病毒能力要弱一些,但它良好的协同抗病毒活性及明显的增强特异性免疫活性使它成为有特色和有价值的抗HIV-1药物。

Objective To study the activity of Wuweilingqi capsule alone and the synergy with other anti-HIV-1 inhibitors against various HIV-1 isolates, and investigate its immunological impacts for CD4^＋ and CD8^＋ T cells. Method Wuweilingqi capsule was extracted from a traditional Chinese medicine recipe which contains 5 herbs, it showed anti-retroviral activity in vitro in the cultures of human peripheral blood mononuclear ceils （PBMC） and T cell lines （H9 and MT2）. Results Wuweilingqi capsule inhibited HIV-1018a （an AZT-sensitive clinical isolate） in PBMC and HTLV-ⅢB （a HIV-1 lab isolate） in H9 and MT-2 T cell lines markedly, and the therapeutic indexes （TI） were 96, 84 and 181 separately, but weakly inhibitory activity against HIV-1018c （an AZT-resistant clinical isolate） and chronically infective HTLV-Ill B were demonstrated. Significant synergy against HIV-1018a and HIV-1018c replication between Wuweilingqi capsule and AZT, indinavir or T-20 were observed. In addition, Wuweilingqi capsule significantly increased PBMC proliferation, interferon-gamma secreting cell number with or without a stimulation of PHA or candida. Conclusion Although Wuweilingqi capsule did not show so strong anti-HIV-1 activity as known west drugs in clinical, its good synergy and significant increase of immune activity suggests that it will be an available and characteristic agent against HIV-1 replication.